Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 477-484

  Jin, Xi ^a   Zhao, Wanke ^a   Kirabo, Annet ^b   Park, Sung O ^b   Ho, Wanting T ^a   Sayeski, Peter P ^b   Zhao, Zhizhuang Joe ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CHYMASE; G 6; GROWTH FACTOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PROTEINASE; TRYPTASE; UNCLASSIFIED DRUG;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IMMUNOPATHOGENESIS; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PERITONEAL CAVITY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; SPLEEN; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL PROLIFERATION; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; INTERLEUKIN-3; JANUS KINASE 2; MALE; MAST CELLS; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PRURITUS; SKIN; STEM CELL FACTOR; STILBENES; TIME FACTORS;

EID: 84904266531     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301946     Document Type: Article

References (49)

1. Spivak, J. L. 2002. Polycythemia vera: myths, mechanisms, and management. Blood 100: 4272-4290. (Pubitemid 35429665)
2. Levine, R. L., and D. G. Gilliland. 2008. Myeloproliferative disorders. Blood 112: 2190-2198.
3. Tefferi, A. 2008. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22: 3-13.
4. Landolfi, R., M. A. Nicolazzi, A. Porfidia, and L. Di Gennaro. 2010. Polycythemia vera. Intern. Emerg. Med. 5: 375-384.
5. Diehn, F., and A. Tefferi. 2001. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br. J. Haematol. 115: 619-621. (Pubitemid 34015654)
6. Mesa, R. A., J. Niblack, M. Wadleigh, S. Verstovsek, J. Camoriano, S. Barnes, A. D. Tan, P. J. Atherton, J. A. Sloan, and A. Tefferi. 2007. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109: 68-76. (Pubitemid 46120195)
7. Saini, K. S., M. M. Patnaik, and A. Tefferi. 2010. Polycythemia vera-associated pruritus and its management. Eur. J. Clin. Invest. 40: 828-834.
8. Tefferi, A., and R. Fonseca. 2002. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 99: 2627. (Pubitemid 34525462)
9. Muller, E.W., J. T. deWolf, R. Egger, P. W. Wijermans, P. C. Huijgens, M. R. Halie, and E. Vellenga. 1995. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br. J. Haematol. 89: 313-318.
10. Baldo, A., E. Sammarco, R. Plaitano, V. Martinelli, and G. Monfrecola. 2002. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br. J. Dermatol. 147: 979-981. (Pubitemid 35365447)
11. Galli, S. J., M. Grimbaldeston, and M. Tsai. 2008. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8: 478-486. (Pubitemid 351733419)
12. Dudeck, A., J. Dudeck, J. Scholten, A. Petzold, S. Surianarayanan, A. Köhler, K. Peschke, D. Vöhringer, C. Waskow, T. Krieg, et al. 2011. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34: 973-984.
13. Galli, S. J., and M. Tsai. 2012. IgE and mast cells in allergic disease. Nat. Med. 18: 693-704.
14. Steinhoff, M., U. Neisius, A. Ikoma, M. Fartasch, G. Heyer, P. S. Skov, T. A. Luger, and M. Schmelz. 2003. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23: 6176-6180. (Pubitemid 36875617)
15. Thomsen, J. S., M. Sonne, E. Benfeldt, S. B. Jensen, J. Serup, and T. Menné. 2002. Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br. J. Dermatol. 146: 792-800. (Pubitemid 34539188)
16. Andoh, T., Y. Yageta, H. Takeshima, and Y. Kuraishi. 2004. Intradermal nociceptin elicits itch-associated responses through leukotriene B(4) in mice. J. Invest. Dermatol. 123: 196-201. (Pubitemid 38833481)
17. Pejler, G., E. Rönnberg, I. Waern, and S. Wernersson. 2010. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115: 4981-4990.
18. Ishii, T., J. Wang, W. Zhang, J. Mascarenhas, R. Hoffman, Y. Dai, N. Wisch, and M. Xu. 2009. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 113: 5942-5950.
19. Wang, J., T. Ishii, W. Zhang, S. Sozer, Y. Dai, J. Mascarenhas, V. Najfeld, Z. J. Zhao, R. Hoffman, N. Wisch, and M. Xu. 2009. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Leukemia 23: 1577-1586.
20. Shide, K., H. K. Shimoda, T. Kumano, K. Karube, T. Kameda, K. Takenaka, S. Oku, H. Abe, K. S. Katayose, Y. Kubuki, et al. 2008. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 22: 87-95.
21. Tiedt, R., H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, and R. C. Skoda. 2008. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940.
22. Xing, S., T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao. 2008. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109-5117.
23. Mullally, A., S. W. Lane, B. Ball, C. Megerdichian, R. Okabe, F. Al-Shahrour, M. Paktinat, J. E. Haydu, E. Housman, A. M. Lord, et al. 2010. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17: 584-596.
24. Marty, C., C. Lacout, A. Martin, S. Hasan, S. Jacquot, M. C. Birling, W. Vainchenker, and J. L. Villeval. 2010. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116: 783-787.
25. Akada, H., D. Yan, H. Zou, S. Fiering, R. E. Hutchison, and M. G. Mohi. 2010. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115: 3589-3597.
26. Li, J., D. Spensberger, J. S. Ahn, S. Anand, P. A. Beer, C. Ghevaert, E. Chen, A. Forrai, L. M. Scott, R. Ferreira, et al. 2010. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116: 1528-1538.
27. Shi, K., W. Zhao, Y. Chen, W. T. Ho, P. Yang, and Z. J. Zhao. 2014. Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J. Hematol. Oncol. 7: 25.
28. Kirabo, A., J. Embury, R. Kiss, T. Polgár, M. Gali, A. Majumder, K. S. Bisht, C. R. Cogle, G. M. Keseru, and P. P. Sayeski. 2011. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. J. Biol. Chem. 286: 4280-4291.
29. Jin, X., W. Zhao, K. Shi, W. T. Ho, and Z. J. Zhao. 2013. Generation of a new congenic mouse strain with enhanced chymase expression in mast cells. PLoS ONE 8: e84340.
30. Guo, Y., Y. Chen, X. Xu, X. Fu, and Z. J. Zhao. 2012. SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J. Hematol. Oncol. 5: 72.
31. Baba, Y., K. Nishida, Y. Fujii, T. Hirano, M. Hikida, and T. Kurosaki. 2008. Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat. Immunol. 9: 81-88. (Pubitemid 350286207)
32. Verstovsek, S., H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-Franco, D. A. Thomas, Z. Estrov, J. S. Fridman, E. C. Bradley, S. Erickson-Viitanen, et al. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363: 1117-1127.
33. LaFave, L. M., and R. L. Levine. 2012. JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol. Sci. 33: 574-582.
34. Mesa, R. A., and J. Cortes. 2013. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J. Hematol. Oncol. 6: 79.
35. Kiss, R., T. Polgár, A. Kirabo, J. Sayyah, N. C. Figueroa, A. F. List, L. Sokol, K. S. Zuckerman, M. Gali, K. S. Bisht, et al. 2009. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg. Med. Chem. Lett. 19: 3598-3601.
36. Majumder, A., L. Govindasamy, A. Magis, R. Kiss, T. Polgár, R. Baskin, R. W. Allan, M. Agbandje-McKenna, G. W. Reuther, G. M. Keseru, et al. 2010. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. J. Biol. Chem. 285: 31399-31407.
37. Kirabo, A., S. O. Park, A. Majumder, M. Gali, M. K. Reinhard, H. L. Wamsley, Z. J. Zhao, C. R. Cogle, K. S. Bisht, G. M. Keserü, and P. P. Sayeski. 2011. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia 13: 1058-1068.
38. Castells, M. C. 2004. Mastocytosis: classification, diagnosis, and clinical presentation. Allergy Asthma Proc. 25: 33-36. (Pubitemid 38365566)
39. Kawakami, T., T. Ando, M. Kimura, B. S. Wilson, and Y. Kawakami. 2009. Mast cells in atopic dermatitis. Curr. Opin. Immunol. 21: 666-678.
40. Rukwied, R., G. Lischetzki, F. McGlone, G. Heyer, and M. Schmelz. 2000. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br. J. Dermatol. 142: 1114-1120. (Pubitemid 30418296)
41. Abdel-Naser, M. B., M. S. Zaki, M. H. Mousa, H. Hamed, M. S. Rizk, H. E. Mohamed, and M. A. Habib. 2007. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera. J. Cutan. Pathol. 34: 924-929. (Pubitemid 350132011)
42. Jackson, N., D. Burt, J. Crocker, and B. Boughton. 1987. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. Br. J. Dermatol. 116: 21-29. (Pubitemid 17216801)
43. Buchanan, J. G., R. V. Ameratunga, and R. C. Hawkins. 1994. Polycythemia vera and water-induced pruritus: evidence against mast cell involvement. Pathology 26: 43-45. (Pubitemid 24047203)
44. Horny, H. P. 2009. Mastocytosis: an unusual clonal disorder of bone marrowderived hematopoietic progenitor cells. Am. J. Clin. Pathol. 132: 438-447.
45. Reid, C. D. 1988. Pruritus preceding the development of polycythaemia vera. Lancet 2: 964.
46. Gerlini, G., F. Prignano, and N. Pimpinelli. 2002. Acute leucocytoclastic vasculitis and aquagenic pruritus long preceding polycythemia rubra vera. Eur. J. Dermatol. 12: 270-271. (Pubitemid 34454658)
47. Zhao, R., S. Xing, Z. Li, X. Fu, Q. Li, S. B. Krantz, and Z. J. Zhao. 2005. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280: 22788-22792. (Pubitemid 40853184)
48. Halova, I., L. Draberova, and P. Draber. 2012. Mast cell chemotaxis-chemoattractants and signaling pathways. Front. Immunol. 3: 119.
49. Yamaki, K., and S. Yoshino. 2014. Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice. Int. Immunopharmacol. 18: 217-224.